RESUMEN
This study, conducted in the Republic of North Ossetia-Alania (RNOA), aimed to explore the genetic landscape of hyperphenylalaninemia (HPA) and phenylketonuria (PKU) in the Ossetian population using data from newborn screening (NBS). Through comprehensive molecular genetic analysis of 29 patients with HPA from diverse ethnic backgrounds, two major genetic variants in the PAH gene, P281L and P211T, were identified, constituting 50% of all detected pathogenic alleles in Ossetian patients. Remarkably, these variants exhibited an exceptionally high frequency in the Ossetian population, surpassing global prevalence rates. This study unveiled a notable prevalence of mild forms of HPA (78%), underscoring the importance of genetic counseling for carriers of pathogenic variants in the PAH gene. Moreover, the findings emphasized the necessity for ongoing monitoring of patients with mild forms, as they may lack significant symptoms for diagnosis, potentially impacting offspring. Overall, this research offers valuable insights into the genetic landscape of HPA and PKU in the Ossetian population.
Asunto(s)
Fenilalanina Hidroxilasa , Fenilcetonurias , Humanos , Fenilcetonurias/genética , Fenilcetonurias/epidemiología , Femenino , Fenilalanina Hidroxilasa/genética , Masculino , Recién Nacido , Tamizaje Neonatal , Alelos , Frecuencia de los GenesRESUMEN
OBJECTIVES: To analyze the results of neonatal screening for congenital hypothyroidism (CH) and hyperphenylalaninemia (HPA) in Zhejiang province from 1999 to 2022. METHODS: A total of 11 922 318 newborns were screened from September 1999 and December 2022 in Zhejiang province. The blood thyroid stimulating hormone (TSH) levels were measured by a fluorescence method and blood phenylalanine (Phe) levels were measured by fluorescence method or tandem mass spectrometry. TSH≥9 µIU/mL was considered positive for CH, while Phe>120 µmol/L and/or Phe/Tyr ratio>2.0 were considered positive for HPA. The positive newborns in screening were recalled, and the gene variations were detected by high-throughput sequencing and MassARRAY tests. RESULTS: The overall neonatal screening rate during 1999-2022 was 89.41% (11 922 318/13 333 929) and the screening rate was increased from 6.46% in 1999 to 100.0% in 2022. A total of 8924 cases of CH were diagnosed among screened newborns with an incidence rate of 1/1336. A total of 563 cases of HPA were diagnosed, including 508 cases of classic phenylketonuria (cPKU) and 55 cases of tetrahydrobiopterin deficiency (BH4D), with an incidence rate of 1/21 176. Ninety-seven out of 8924 cases of CH underwent genetic analysis. Gene mutations were detected in 9 CH related genes, the highest frequency mutations were found in DUOX2 gene (69.0%) with c.3329G>A (p.R1110Q) (18.2%) and c.1588A>T (p.K530X) (17.3%) as the hotspot mutations. There were 81 PAH gene variants detected in a total of 250 cases of cPKU, and c728G>A (p.R243Q) (24.4%), c.721C>T (p.R241C) (15.0%) were the hotspot mutations. Meanwhile 7 novel variants in PAH gene were detected: c.107C>A (p.S36*), c.137G>T (p.G46V), c.148A>G(p.K50E), c.285C>T (p.I95I), c.843-10delTTCC, exon4-7del and c.1066-2A>G. There were 12 PTS gene variants detected in 36 cases of BH4D, and c.259C>T (p.P87S) (31.9%) was the hotspot mutation. CONCLUSIONS: The incident of CH has increased from 1999 to 2022 in Zhejiang province, and it is higher than that of national and global levels; while the incidence of HPA is similar to the national average. DUOX2 gene variation is the most common in CH patients; c.728G>A (p.R243Q) is the hotspot mutation in cPKU patients, while c.259C>T (p.P87S) is the hotspot mutation in BH4D patients.
Asunto(s)
Hipotiroidismo Congénito , Fenilcetonurias , Humanos , Recién Nacido , Tamizaje Neonatal , Oxidasas Duales , Hipotiroidismo Congénito/diagnóstico , Hipotiroidismo Congénito/epidemiología , Hipotiroidismo Congénito/genética , Fenilcetonurias/diagnóstico , Fenilcetonurias/epidemiología , Fenilcetonurias/genética , TirotropinaRESUMEN
BACKGROUND: Phenylketonuria (PKU) is an inborn error of phenylalanine (Phe) metabolism that, if untreated, causes Phe accumulation in the brain leading to neurophysiologic alterations and poor outcomes. Lifelong management centers on dietary Phe restriction, yet long-term complete metabolic control is unachievable for many adults. High blood Phe levels or chronic Phe and intact protein restriction in the diet may lead to somatic comorbidities. A systematic literature review was conducted to evaluate somatic comorbidities experienced by adults with PKU. METHODS: Clinical and observational studies reporting somatic comorbidities experienced by individuals with PKU aged ≥ 16 years (or classified as adults) evaluating a Phe-restricted diet with or without pharmacologic therapy versus no therapeutic intervention (including healthy controls), or pharmacologic therapy versus a Phe-restricted diet alone, were identified. PubMed® was searched (February 1, 2022 and updated November 1, 2023), using a pre-defined search strategy, followed by two-stage screening and data extraction. Included studies were grouped by PKU population comparison. RESULTS: 1185 records were screened; 51 studies across 12,602 individuals were extracted. Bone-related abnormalities were the most reported outcome (n = 21); several outcome measures were used. Original study groupings included: Phe-restricted diet versus healthy controls or reference values (n = 40); treatment-adherent versus those non-adherent (n = 12). Additional groups added as part of a protocol amendment included: different Phe-restricted diets (n = 4); severe versus less severe disease (n = 5). Vote counting indicated a higher burden of ≥ 1 comorbidity (or outcome measure) for the Phe-restricted diet group by 37 of 38 studies included in the analysis of Phe-restricted diet versus healthy controls; higher burden in healthy controls was reported in 12 studies. Vote counting was similar between those treatment adherent (n = 7) versus non-adherent (n = 10). CONCLUSIONS: Adults with PKU have a higher comorbidity burden than a non-PKU population. More robust studies are needed to better understand the relationship between effective metabolic control and comorbidity burden, using consistent outcome measures. This SLR was supported by BioMarin Pharmaceutical Inc., Novato, CA, and is registered with the Research Registry (reviewregistry1476).
Asunto(s)
Comorbilidad , Fenilcetonurias , Humanos , Fenilcetonurias/dietoterapia , Fenilcetonurias/epidemiología , Adulto , Fenilalanina/sangreRESUMEN
BACKGROUND: There is a notable lack of harmonisation in newborn screening (NBS) programmes worldwide. The Galician programme for early detection of inborn errors of metabolism (IEM) was one of the first NBS programmes in Europe to incorporate mass spectrometry (July 2000). This programme currently screens for 26 IEMs in dried blood and urine samples collected 24-72 h after birth. RESULTS: In its 22-year history, this programme has analysed samples from 440,723 neonates and identified 326 cases of IEM with a prevalence of 1:1351. The most prevalent IEMs were hyperphenylalaninaemia (n = 118), followed by medium chain acyl-CoA dehydrogenase deficiency (MCADD, n = 26), galactosaemia (n = 20), and cystinurias (n = 43). Sixty-one false positives and 18 conditions related to maternal pathologies were detected. Urine samples have been identified as a useful secondary sample to reduce the rate of false positives and identify new defects. There were 5 false negatives. The overall positive value was 84.23%. The fatality rate over a median of 12.1 years of follow-up was 2.76%. The intelligence quotient of patients was normal in 95.7% of cases, and school performance was largely optimal, with pedagogic special needs assistance required in < 10% of cases. Clinical onset of disease preceded diagnosis in 4% of cases. The age at which first NBS report is performed was reduced by 4 days since 2021. CONCLUSIONS: This study highlights the benefits of collecting urine samples, reduce NBS reporting time and expanding the number of IEMs included in NBS programmes.
Asunto(s)
Errores Innatos del Metabolismo , Tamizaje Neonatal , Humanos , Tamizaje Neonatal/métodos , Recién Nacido , Errores Innatos del Metabolismo/diagnóstico , Femenino , Masculino , Galactosemias/diagnóstico , Errores Innatos del Metabolismo Lipídico/diagnóstico , Fenilcetonurias/diagnóstico , Fenilcetonurias/epidemiología , Estudios de Seguimiento , España , Acil-CoA Deshidrogenasa/deficienciaRESUMEN
Abstract Objective: To estimate the prevalence and factors associated with overweight/obesity development in adolescents with early diagnosed phenylketonuria treated exclusively by diet. Methodology: In this cross-sectional study anthropometric measurements, serum phenylalanine levels, and 10 metabolites associated with lipid and carbohydrate metabolism were analyzed in 101 adolescents aged 10-20 years. Adolescents were categorized into overweight/obesity and eutrophic/low body mass index groups. These patients were compared using Student's t-test, Pearson's chi-square test, Wald's chi-square test for multivariate analysis. Further, to verify whether the prevalence of overweight/obesity found in the study population was similar to that in the general population, the authors compared the nutritional status of 46 patients aged 13-17 years with that of healthy students of the same age from the National School Health Survey using the chi-square test for adherence. The significance threshold was p < 0.5. Results: The prevalence of overweight/obesity in adolescents was 27.7%. There was no difference in prevalence between sexes. Older age was a protective factor and Increased Homeostasis Model Assessment Insulin Resistance index and high phenylalanine and low-density lipoprotein cholesterol levels were predictive factors for overweight/obesity. The equality hypothesis was not rejected in the comparison of nutritional states of 46 patients aged 13-17 years and healthy students of the same age. Conclusion: The prevalence of overweight/obesity in phenylketonuria adolescents was similar to what is found in healthy adolescents.
Asunto(s)
Humanos , Niño , Adolescente , Adulto , Adulto Joven , Fenilcetonurias/complicaciones , Fenilcetonurias/epidemiología , Obesidad Infantil/complicaciones , Obesidad Infantil/epidemiología , Índice de Masa Corporal , Prevalencia , Estudios Transversales , Causalidad , Sobrepeso/complicaciones , Sobrepeso/diagnóstico , Sobrepeso/epidemiologíaRESUMEN
ABSTRACT Objective: To characterize metabolic control and verify whether it has any relation with socioeconomic, demographic, and body composition variables in children and adolescents with phenylketonuria (PKU) diagnosed in the neonatal period. Methods: This cohort study collected retrospective data of 53 phenylketonuric children and adolescents. Data on family income, housing, and mother's age and schooling level were collected, and anthropometric measures of body composition and distribution were taken. All dosages of phenylalanine (Phe) from the last five years (2015-2019) were evaluated and classified regarding their adequacy (cutoffs: 0-12 years: 2-6 mg/dL; 12-19 years: 2-10 mg/dL). Adequate metabolic control was considered if ≥7%) of the dosages were within desired ranges. Results: The mean (±standard deviation) age in the last year was 10.1±4.6 years. Most of them were under 12 years old (33/53; 62.3%) and had the classic form of the disease (39/53; 73.6%). Better metabolic control was observed among adolescents (68.4 versus 51.4%; p=0.019). Overweight was found in 9/53 (17%) and higher serum Phe levels (p<0.001) were found in this group of patients. Metabolic control with 70% or more Phe level adequacy decreased along with the arm muscle area (AMA) (ptendency=0.042), being 70.0% among those with low reserve (low AMA), and 18.5% among those with excessive reserve (high AMA). Conclusions: Adequate metabolic control was observed in most patients. The findings suggest that, in this sample, the levels of phenylalanine may be related to changes in body composition.
RESUMO Objetivo: Caracterizar o controle metabólico e verificar se existe relação entre ele, variáveis socioeconômicas, demográficas e composição corporal de crianças e adolescentes com fenilcetonúria (FNC) diagnosticada no período neonatal. Métodos: Coorte com coleta retrospectiva de dados de 53 crianças e adolescentes fenilcetonúricos. Foram coletados dados de renda familiar, moradia, idade e escolaridade materna e realizaram-se medidas antropométricas de composição e distribuição corporal. Todas as dosagens de fenilalanina (Fal) dos últimos cinco anos (2015-2019) foram avaliadas e classificadas quanto à adequação (cortes: 0-12 anos: 2-6 mg/dL; 12-19 anos: 2-10 mg/dL). A proporção de dosagens adequadas ≥70% foi considerada como controle metabólico adequado. Resultados: A média (±desvio padrão) de idade, no último ano, foi de 10,1±4,6 anos. A maioria tinha menos de 12 anos (33/53; 62,3%) e apresentava a forma clássica da doença (39/53; 73,6%). Observou-se melhor controle metabólico entre os adolescentes (68,4 vs. 51,4%; p=0,019). Excesso de peso foi encontrado em 9/53 (17%) e maiores níveis séricos de Fal foram descritos nesse grupo (p<0,001). O percentual de controle metabólico com 70% ou mais de adequação dos níveis de Fal foi decrescente de acordo com a área muscular do braço (AMB; ptendência=0,042), sendo de 70% entre os de baixa reserva (AMB reduzida) e de 18,5% entre os com excesso (AMB elevada). Conclusões: Observou-se controle metabólico adequado na maioria dos avaliados e os achados sugerem que, nesta amostra, os níveis de fenilalanina podem estar relacionados com alterações da composição corporal.
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Preescolar , Niño , Adolescente , Fenilalanina/sangre , Fenilcetonurias/diagnóstico , Fenilcetonurias/metabolismo , Composición Corporal/fisiología , Errores Innatos del Metabolismo/diagnóstico , Fenilcetonurias/epidemiología , Factores Socioeconómicos , Estudios de Casos y Controles , Antropometría/métodos , Demografía , Estado Nutricional , Estudios Retrospectivos , Estudios de Cohortes , Sobrepeso/epidemiología , Errores Innatos del Metabolismo/sangre , Errores Innatos del Metabolismo/epidemiologíaRESUMEN
Introduction: Newborn screening allows the screening of diseases that are still in the asymptomatic period and whose early diagnosis and treatment are associated with reduced infant morbidity and mortality. The aim of this study was to evaluate the public National Newborn Screening Program in the municipality of Carazinho, state of Rio Grande do Sul (RS), Brazil. Methods: This was a population-based, retrospective, descriptive study. We collected and transcribed data from a database of the Carazinho municipal laboratory, which is affiliated with the referral center for newborn screening in RS. The records of all individuals undergoing newborn screening from 2005 to 2010 were reviewed, and information was collected on the program coverage, time elapsed between birth and screening (first collection), and test results. Results: The program had a coverage of 75.5%. One suspected case of phenylketonuria, three suspected cases of congenital hypothyroidism and no suspected cases of hemoglobinopathy were identified. In addition, there were 18 positive results for hemoglobin S heterozygosity, five for hemoglobin D heterozygosity, two for hemoglobin C heterozygosity, and one for a rare variant hemoglobin. When analyzing the newborn's age at the time of blood collection, it was observed that 63.1% were within the recommended age range. Conclusions: Our findings suggest the need for optimization of public newborn screening in the evaluated municipality. The strategies to be adopted should include education of the population and especially of managers and health professionals about the importance of newborn screening. (AU)
Asunto(s)
Humanos , Recién Nacido , Fenilcetonurias/epidemiología , Tamizaje Neonatal/métodos , Hemoglobinopatías/epidemiología , Salud Pública/estadística & datos numéricosRESUMEN
Abstract Objectives To show the general prevalence and to characterize tetrahydrobiopterin (BH4) deficiencies with hyperphenylalaninemia, identified by the Neonatal Screening Program of the State of Minas Gerais. Methods Descriptive study of patients with BH4 deficiency identified by the Neonatal Screening Program of the State of Minas Gerais. Results The prevalence found was 2.1 for 1,000,000 live births, with a frequency of 1.71% among hyperphenylalaninemias. There were four cases (40%) with 6-pyruvoyl-tetrahydropterin synthase deficiency, three with GTP cyclohydrolase I - autosomal recessive form deficiency, and three with dihydropteridine reductase deficiency (30% each). Six patients were diagnosed due to clinical suspicion and four cases due to systematic screening in neonatal screening. After the start of the treatment, patients identified by neonatal screening had rapid improvement and improved neuropsychomotor development compared to those diagnosed by the medical history. Conclusions The prevalence of BH4 deficiencies in Minas Gerais was slightly higher than that found in the literature, but the frequency among hyperphenylalaninemias was similar. Although rare, they are severe diseases and, if left untreated, lead to developmental delays, abnormal movements, seizures, and premature death. Early treatment onset (starting before 5 months of age) showed good results in preventing intellectual disability, justifying the screening of these deficiencies in newborns with hyperphenylalaninemia identified at the neonatal screening programs for phenylketonuria.
Resumo Objetivos Apresentar a prevalência geral e caracterizar as deficiências de tetrahidrobiopterina - BH4 - com hiperfenilalaninemia, identificadas pelo Programa de Triagem Neonatal do Estadode Minas Gerais. Métodos Estudo descritivo de pacientes com deficiência de BH4 do Programa de Triagem Neonatal do Estado de Minas Gerais. Resultados A prevalência encontrada foi de 2,1 para 1.000.000 recém-nascidos vivos e a frequência de 1,71%, dentre as hiperfenilalaninemias. Quatro casos (40%) com deficiência de 6-piruvoil-tetrahidropterina sintase, três com deficiência de GTP ciclohidrolase I e três com deficiência de dihidropteridina redutase (30% cada um). Seis pacientes foram diagnosticadospor suspeita clínica e quatro pela pesquisa sistemática na triagem neonatal. Após o início do tratamento, os pacientes identificados pela triagem neonatal tiveram melhora rápida e melhor desenvolvimento neuropsicomotor em comparação com aqueles diagnosticados pela história clínica. Conclusões A prevalência das deficiências de BH4 em Minas Gerais foi um pouco maior que a encontrada na literatura, mas a frequência, entre as hiperfenilalaninemias, foi semelhante. Embora raras, são graves e, se não tratadas, levam a atraso de desenvolvimento, movimentos anormais, convulsões e morte precoce. O tratamento precoce (início antes dos 5 meses) mostrou bons resultados na prevenção de deficiência intelectual, justificando a pesquisa dessas deficiências nos recém-nascidos com hiperfenilalaninemia pelos programas de triagem neonatalpara fenilcetonúria.
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Fenilcetonurias/diagnóstico , Liasas de Fósforo-Oxígeno/deficiencia , Fenilcetonurias/complicaciones , Fenilcetonurias/epidemiología , Brasil/epidemiología , Prevalencia , Estudios Transversales , Estudios Retrospectivos , Tamizaje NeonatalRESUMEN
Los errores innatos del metabolismo comprenden un amplio grupo de patologías, habitualmente con una alta morbimortalidad. Son poco conocidas por parte de la comunidad médica debido a su baja prevalencia, y las dificultades en su diagnóstico y tratamiento hacen que sea imprescindible su manejo en Unidades especializadas. La Unidad de Enfermedades Metabólicas del Hospital Ramón y Cajal fue pionera en el estudio de estos pacientes, y es hoy un referente ¡mundial en la asistencia e investigación en este campo (AU)
Inborn errors of metabolism are an extensive group of diseases that usually have high morbility and mortality. They are little known within the medical community due to their low prevalence, which coupled with the difficulties in their diagnosis and treatment make it indispensable for them to be handled in specialized units. The Metabolic Department of the Ramón y Cajal was a pioneer in the study of these patients and is nowadavs a worldwide recognized center in the treatment and investigation in this field (AU)
Asunto(s)
Humanos , Masculino , Femenino , Niño , Enfermedades Metabólicas/epidemiología , Enfermedades Metabólicas/prevención & control , Comisión sobre Actividades Profesionales y Hospitalarias/normas , Errores Innatos del Metabolismo Lipídico/epidemiología , Errores Innatos del Metabolismo/epidemiología , Fenilcetonurias/complicaciones , Fenilcetonurias/epidemiología , Hipoglucemia/epidemiología , Hiperamonemia/epidemiología , Unidades Hospitalarias/organización & administración , Unidades Hospitalarias/normas , Evaluación de Necesidades/organización & administraciónRESUMEN
Objectives: Phenylketonuria (PKU) was the first inherited metabolic disease known to cause mental retardation for which a newborn screening program (NBS) was developed. The objective of this study was to evaluate the effectiveness of PKU NBS and the management of cases in the northeastern Brazilian state of Sergipe (SE).Materials and methods: We reviewed the phenylalanine concentrations in filter-paper collected from the heel (PKUneo) of 43,449 newborns; blood concentrations obtained by venipuncture in the subjects with abnormal PKUneo; the children’s age at several phases of the program, the incidence of the disease from January 2007 to June 2008; and metabolic control of the patients.Results: The coverage of NBS/SE was 78.93%. The children’s age was 10 ± 7 days at PKUneo collection. Twelve children were recalled based on the PKUneo cutoff value at 28 ± 13 days. From these, the concentrations of phenylalanine collected by venipuncture were normal in five children. The incidence of hyperphenylalaninemia was 1/43,449, and of PKU was 1/8,690 (5 cases). One suspected subject died. Another death occurred in the cohort, in a confirmed PKU case. PKU treatment began within 51 ± 12 days of life. In the four patients under dietary phenylalanine restriction, metabolic control was often difficult.Conclusions: PKU NBS/SE has satisfactory coverage and adequate cutoff for recalling patients and diagnosis, but the onset of treatment is delayed, and follow-up metabolic control is frequently inadequate.
Objetivos: A fenilcetonúria (PKU) foi a primeira causa metabólica hereditária de retardamento mental para a qual foi desenvolvido um programa de triagem em recém-nascidos (NBS). O objetivo deste estudo foi avaliar a eficácia do NBS para a PKU e o manejo dos casos em Sergipe (SE), Brasil.Materiais e métodos: Revisamos as concentrações de fenilalanina no filtro de papel coletado do calcanhar (PKUneo) de 43.449 recém-nascidos, suas concentrações de sangue obtidas por punção venosa em indivíduos com PKUneo anormal, a idade das crianças em diversas fases do programa, a incidência da doença no período de janeiro de 2007 a junho de 2008 e o controle metabólico dos pacientes.Resultados: A cobertura da NBS/SE foi de 78,93%. A idade das crianças era de 10 ± 7 dias na coleta de PKUneo. Doze crianças foram reconvocadas com base no ponto de corte de PKUneo aos 28 ± 13 dias de idade. Destas, as concentrações de fenilalanina por venipunctura foram normais em cinco. A incidência da hiperfenilalaninemia foi 1/43.449 e de PKU foi 1/8.690 (5 casos), e um indivíduo suspeito foi a óbito. Outro óbito ocorreu na coorte em um caso de PKU confirmado. O tratamento para a PKU começou com 51 ± 12 dias. Nos quatro pacientes sob restrição de fenilalanina alimentar, o controle metabólico foi frequentemente difícil.Conclusões: PKU NBS/SE apresenta uma cobertura satisfatória e ponto de corte adequado para reconvocação e diagnóstico, mas o início do tratamento é atrasado e o controle no seguimento é frequentemente inadequado.
Asunto(s)
Femenino , Humanos , Lactante , Recién Nacido , Masculino , Tamizaje Neonatal/normas , Evaluación de Programas y Proyectos de Salud , Fenilalanina/sangre , Fenilcetonurias/diagnóstico , Biomarcadores/sangre , Recolección de Muestras de Sangre/métodos , Brasil/epidemiología , Estudios Transversales , Incidencia , Modelos Lineales , Fenilcetonurias/epidemiología , Valores de ReferenciaRESUMEN
OBJETIVO: Avaliar a prevalência das patologias fenilcetonúria (FNC), hipotireoidismo congênito (HC), fibrose cística (FC), hemoglobinopatias (HB) e hiperplasia adrenal congênita (HAC), no Estado de Santa Catarina, a fim de delinear o perfil da população catarinense em relação a essas patologias. MATERIAIS E MÉTODOS: Foi realizado um levantamento de dados do Programa de Triagem Neonatal da Secretaria de Estado da Saúde de Santa Catarina, no período de 2004 a 2008. RESULTADOS: No período de estudo, foram obtidas as seguintes prevalências: FCN 1:28.862, HC 1:2.876, FC 1:5.121, HB S 1:14.446 e para HAC 1:11.655 crianças triadas. CONCLUSÕES: A prevalência média da FNC mostrou-se inferior à prevalência nacional, ao passo que a da HAC foi superior; por sua vez, a do HC mostrou-se semelhante às prevalências mundial e nacional. Além disso, o predomínio da população caucasiana no Estado resultou em uma prevalência reduzida da HB e uma prevalência aumentada da FC em relação ao restante do país.
OBJECTIVE: To evaluate the prevalence of the diseases phenylketonuria (PKU), congenital hypothyroidism (CH), cystic fibrosis (CF), hemoglobinopathies (HB), and congenital adrenal hyperplasia (CAH), in the state of Santa Catarina, in order to delineate the local population profile for these diseases. MATERIALS AND METHODS: A survey of data from the Newborn Screening Program of the Ministry of Health of Santa Catarina, in the period 2004 to 2008 was carried out. RESULTS: During the study period, the following prevalences were obtained: 1:28,862 children screened for PKU; 1:2,876 children screened for CH; 1:5,121 children screened for CF; 1:14,446 children screened for HB S; and 1:11,655 children screened for CAH. CONCLUSIONS: The prevalence of PKU proved to be lesser than the national prevalence, while CAH prevalence was greater. On the other hand CH prevalence was similar to the global and national prevalence. Moreover, the predominance of the Caucasian population in the state resulted in reduced prevalence of HB S and increased prevalence of CF in relation to the rest of the country.
Asunto(s)
Humanos , Recién Nacido , Hiperplasia Suprarrenal Congénita/epidemiología , Hipotiroidismo Congénito/epidemiología , Fibrosis Quística/epidemiología , Hemoglobinopatías/epidemiología , Fenilcetonurias/epidemiología , Brasil/epidemiología , Programas Nacionales de Salud/estadística & datos numéricos , Prevalencia , Estudios RetrospectivosRESUMEN
OBJETIVO: Avaliar o Programa de Triagem Neonatal do Estado do Tocantins de 1995 a 2011. MATERIAIS E MÉTODOS: A coleta de dados foi realizada por meio de entrevista com os responsáveis pelo serviço, por análise de prontuários de pacientes com diagnóstico de fenilcetonúria (PKU) ou hipotireoidismo congênito (HC) atendidos pelo programa e por entrevista com pais e/ou responsáveis por pacientes em acompanhamento. RESULTADOS: A cobertura de triagem neonatal aumentou de 32,3% para 76,6% depois da implantação do Programa Nacional de Triagem Neonatal (PNTN). A prevalência de PKU e de HC no período analisado foi de 1:28.309 e de 1:4.632 nascidos vivos, respectivamente. A idade média das crianças na coleta da primeira amostra de sangue (PKU: 9,6 ± 6,3 dias; HC: 13,3 ± 10,3 dias) e no início do tratamento (PKU: 57,0 ± 17,6 dias; HC: 95,6 ± 57,6 dias) foi superior às preconizadas pelo Ministério da Saúde. A avaliação dos pais sobre a qualidade do acompanhamento realizado foi classificada como satisfatória por 100% dos entrevistados. CONCLUSÃO: Embora tenha havido grande evolução do programa de triagem neonatal deste Estado, há necessidade de maior incentivo governamental para que o programa seja otimizado e possa avançar para as fases seguintes do PNTN.
OBJECTIVE: To evaluate the Neonatal Screening Program in the State of Tocantins from 1995 to 2011. MATERIALS AND METHODS: Data collection was conducted by means of interviews with those responsible for the service, by the analysis of medical records of patients diagnosed with phenylketonuria (PKU) and congenital hypothyroidism (CH) that were enrolled in the program, and by interviews with parents and/or guardians of the patients monitored. RESULTS: Program coverage increased from 32.3% to 76.6% after the implementation of the National Newborn Screening Program (PNTN). The prevalence of PKU and CH was 1:28,309 and 1:4,632 live births, respectively. The mean ages at the collection of the first blood sample (PKU: 9.6 ± 6.3 days; CH: 13.3 ± 10.3 days) and at the beginning of the treatment (PKU: 57.0 ± 17.6 days; CH: 95,6 ± 57.6 days) were greater than recommended by the Ministry of Health. The quality of monitoring was considered satisfactory by 100% of the parents. CONCLUSION: Although there have been great developments in neonatal screening program in this state, there is need for greater government incentives to optimize the program and to make the PNTN advance to its next phases.
Asunto(s)
Femenino , Humanos , Recién Nacido , Masculino , Hipotiroidismo Congénito/diagnóstico , Tamizaje Neonatal/normas , Fenilcetonurias/diagnóstico , Brasil/epidemiología , Estudios Transversales , Hipotiroidismo Congénito/epidemiología , Programas Nacionales de Salud , Prevalencia , Evaluación de Programas y Proyectos de Salud , Fenilcetonurias/epidemiología , Garantía de la Calidad de Atención de SaludRESUMEN
In this study, the frequency of detected congenital hypothyroidism, phenylketonuria and haemoglobinopathies in the State of Rio de Janeiro's (Brazil) Newborn Screening Program (NBSP) was analyzed between the years of 2005 and 2007. There were two Newborn Screening Reference Centers (named NSRC A and B) with programmatic differences. In 2007, overall detection coverage reached 80.7%. The increase in the incidence of congenital hypothyroidism (1:1,030 in 2007) was attributed to the reduction of neonatal TSH value limits over time. The incidence discrepancy of phenylketonuria between NSRC A (1:28,427) and B (1:16,522) might be partially explained by the small number of cases. The incidence of sickle cell disease and its traits were uniformly high (1:1,288 and 1:21, respectively). This was coherent with the ethnic composition of the population. The differences in laboratory methods and critical values, in addition to other programmatic issues, may explain the variances in the results and limited analysis of the role of biological and environmental determinants in the occurrence of these diseases.
Neste estudo, foi analisada a frequência de detecção do hipotireoidismo congênito, fenilcetonúria e hemoglobinopatias no Programa de Triagem Neonatal do Estado do Rio de Janeiro, Brasil, entre 2005 e 2007. Havia dois Serviços de Referência em Triagem Neonatal (designados SRTN A e B) com diferenças programáticas. Em 2007, a cobertura alcançou 80,7%. O aumento na incidência do hipotireoidismo congênito (1:1.030 em 2007) foi atribuído à redução no valor de corte do TSH ao longo do tempo. As incidências discrepantes da fenilcetonúria entre os modelos (SRTN A - 1:28.427; SR-TN B - 1:16.522) podem ser parcialmente explicadas pelo pequeno número de casos. A incidência da doença falciforme e do traço falcêmico foi uniformemente elevada (1:1.288 e 1:21, respectivamente), sendo coerente com a composição étnica da população. As diferenças nos métodos laboratoriais e valores críticos, além de outras questões programáticas, podem explicar a variabilidade nos resultados e limitar a análise do papel dos determinantes biológicos e ambientais sobre a ocorrência das doenças.
Asunto(s)
Humanos , Recién Nacido , Hipotiroidismo Congénito/epidemiología , Hemoglobinopatías/epidemiología , Tamizaje Neonatal , Fenilcetonurias/epidemiología , Brasil/epidemiología , Hipotiroidismo Congénito/diagnóstico , Hemoglobinopatías/diagnóstico , Incidencia , Fenilcetonurias/diagnóstico , Estudios Retrospectivos , Enfermedades Raras/diagnóstico , Enfermedades Raras/epidemiologíaRESUMEN
OBJETIVO:Descrever as características clínicas e demográficas dos pacientes com diagnóstico de hiperfenilalaninemia acompanhados no Serviço de Referência em Triagem Neonatal da Bahia. MÉTODOS: Estudo transversal de 99 famílias (111 afetados) com fenótipo bioquímico de hiperfenilalaninemia, com coleta de dados em prontuários e em banco de dados laboratorial, incluindo aspectos demográficos e clínicos. RESULTADOS: A incidência de hiperfenilalaninemia na Bahia foi de um caso a cada 16.334 nascidos vivos, com cobertura de 91 por cento. Dentre os pacientes acompanhados, 82 por cento foram diagnosticados pela triagem neonatal e, em 11 famílias, havia mais de um caso. O fenótipo clássico da fenilcetonúria foi diagnosticado em 63 (57 por cento) pacientes. Entre os triados, a mediana de idade na primeira consulta foi 39,5 dias e, deles, 34 por cento apresentavam sintomatologia nesse momento; nenhum com atraso no desenvolvimento neuropsicomotor. A consanguinidade foi descrita em 32 por cento dos casos e houve predomínio de pacientes classificados como brancos (63 por cento). Os pais tinham baixa escolaridade e baixa renda. Dos 417 municípios da Bahia, 15 por cento apresentavam pelo menos um caso, com concentração na região nordeste (10 por cento) e na capital do Estado (14 por cento). CONCLUSÕES: Os resultados evidenciaram idade tardia ao início do tratamento, o que pode comprometer os resultados do programa. Observou-se também presença de consanguinidade e recorrência familiar, reforçando a importância da investigação familiar para diagnosticar indivíduos com deficiência mental de etiologia não esclarecida que podem se beneficiar de tratamento.
OBJECTIVE:To describe demographic and clinical characteristics of patients with hyperphenylalaninemia followed at the Neonatal Screening Reference Service of Bahia, Brazil. METHOD:Cross-sectional study including 99 families (111 affected individuals) with biochemical phenotype of hyperphenylalaninemia by chart review and laboratory database that include demographic and clinical features. RESULTS: The incidence of hyperphenylalaninemia in Bahia was one case per 16,334 live births, covering 91 percent of them. Among patients followed, 82 percent were diagnosed by newborn screening and, in 11 families, there were more than one case. The classic phenotype of phenylketonuria was diagnosed in 63 (57 percent) patients. Among those screened, the median age at first consultation was 39.5 days. Among the patients, 34 percent had symptoms at the first medical consultation, none of them with delayed neurodevelopment. Consanguinity was reported in 32 percent of patients. Affected individuals were predominantly classified as white (63 percent). The parents had low education and low income. Among the 417 municipalities of Bahia, 15 percent had at least one case, with a concentration in the Northeast (10 percent) and in the capital of the State (14 percent). CONCLUSIONS: The results showed elevated age at the beginning of the treatment, which may compromise the program results. Presence of consanguinity and familial recurrence were also noted. Careful investigation of families searching for individuals with mental retardation of unknown etiology that would benefit from the treatment is important.
Asunto(s)
Humanos , Fenilcetonurias/epidemiología , Tamizaje NeonatalRESUMEN
O Programa Nacional de Triagem Neonatal (PNTN) implantado no Brasil tem como objetivo, considerando cada fase de execução local, detectar doenças como fenilcetonúria, hipotereoidismo congênito, hemoglobinopatias e fibrose cística. O objetivo deste trabalho foi analisar, através de um estudo transversal e observacional, a prevalência das doenças detectadas pelo PNTN no município de Araraquara emitidas pela APAE de São Paulo no período compreendido entre abril e dezembro de 2009. Os resultados mostram que o município apresentou, no ano de 2009, prevalência de fenilcetonúria e hipotireoidismo congênito de 0,06% acima da média nacional, que é de 0,01% e 0,03%, respectivamente. Com relação às hemoglobinopatias, encontrou-se prevalência do traço para anemia falciforme de 2,15% abaixo da média nacional, que é de 2,6%. A prevalência do traço C no município foi de 0,57%, semelhante a valores nacionais disponíveis na literatura. FA BART´S confirmado apresentou valor de 0,13% abaixo da média de 0,38% da região do município de Araraquara. A realização do teste do pezinho e o aconselhamento aos cuidadores são fatores importantes para redução de morbidades relacionadas à evolução dessas doenças.
The National Neonatal Screening Program (NNSP) set up in all Brazil, aims, through planned phases of local implementation, to detect diseases such as phenylketonuria, congenital hypothyroidism, hemoglobinopathies and cystic fibrosis. The aim of this study was to assess, through a cross-sectional observational study, the prevalence of the diseases detected by the NNSP in the city of Araraquara, in records issued by the São Paulo APAE laboratory in the period between April and December 2009.The results show that Araraquara had a prevalence of phenylketonuria and congenital hypothyroidism 0.06% above the national averages of 0.01% and 0.03% respectively. With respect to hemoglobinopathies, the prevalence of sickle cell trait was 2.15% below the national average of 2.6%. The prevalence of Hb C in the city was 0.57%, similar to national values reported in the literature. Confirmed Hb Bart´s had a prevalence of 0.13% in Araraquara, below the average of 0.38% for the surrounding region. The neonatal screening by heel-prick test and counseling for caregivers are important factors in reducing morbidity related to the evolution of these diseases.
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Anemia de Células Falciformes/epidemiología , Fenilcetonurias/epidemiología , Fibrosis Quística/epidemiología , Hipotiroidismo Congénito/epidemiología , Tamizaje NeonatalRESUMEN
A consistent finding of many studies describing the spectrum of mutant phenylalanine hydroxylase (PAH) alleles underlying hyperphenylalaninemia is the impossibility of achieving a 100% mutation ascertainment rate using conventional gene-scanning methods. These methods include denaturing gradient gel electrophoresis (DGGE), denaturing high performance liquid chromatography (DHPLC), and direct sequencing. In recent years, it has been shown that a significant proportion of undetermined alleles consist of large deletions overlapping one or more exons. These deletions have been difficult to detect in compound heterozygotes using gene-scanning methods due to a masking effect of the non-deleted allele. To date, no systematic search has been carried out for such exon deletions in Italian patients with phenylketonuria or mild hyperphenylalaninemia. We used multiplex ligation- dependent probe amplification (MLPA), comparative multiplex dosage analysis (CMDA), and real-time PCR to search for both large deletions and duplications of the phenylalanine hydroxylase gene in Italian hyperphenylalaninemia patients. Four deletions removing different phenylalanine hydroxylase (PAH) gene exons were identified in 12 patients. Two of these deletions involving exons 4-5-6-7-8 (systematic name c.353-?_912 + ?del) and exon 6 (systematic name c.510-?_706 + ?del) have not been reported previously. In this study, we show that exon deletion of the PAH gene accounts for 1.7% of all mutant PAH alleles in Italian hyperphenylalaninemics.
Asunto(s)
Humanos , Análisis Mutacional de ADN/métodos , Progresión de la Enfermedad , Exones/genética , Frecuencia de los Genes , Italia , Fenilalanina Hidroxilasa/genética , Fenilcetonurias/epidemiología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Eliminación de Secuencia/genéticaRESUMEN
OBJETIVO: Avaliar o Serviço de Referência em Triagem Neonatal para hipotireoidismo congênito e fenilcetonúria no Estado de Mato Grosso. MÉTODOS: Estudo transversal, utilizando-se dados secundários dos exames realizados no período de janeiro de 2003 a dezembro de 2004. RESULTADOS: Foram feitos 66.337 testes de triagem com uma cobertura populacional inferior a 70%. A prevalência de fenilcetonúria foi de 1:33.068 nascidos vivos, e de hipotireoidismo congênito foi de 1:9.448 nascidos vivos. Apenas 22% das amostras foram coletadas na idade recomendada; a maioria realizou o teste de triagem entre 8 e 30 dias de vida. A mediana da idade na coleta do teste foi de 12 dias. Verificou-se que o serviço teve dificuldades na reconvocação dos casos suspeitos e dificuldades financeiras na obtenção dos insumos laboratoriais. CONCLUSÕES: A idade na coleta e o atraso na fase de confirmação diagnóstica foram os principais motivos para o atraso do início do tratamento dos casos detectados pelo serviço.
OBJECTIVE: To evaluate the Reference Center for Neonatal Screening for congenital hypothyroidism and phenylketonuria for the State of Mato Grosso. METHOD: Cross-sectional study using secondary data of screening tests carried out from January 2003 to December 2004. RESULTS: 66,337 exams were conducted with population coverage of less than 70%. The prevalence of phenylketonuria was 1:33,068 live births and of congenital hypothyroidism was 1:9,448 live births. Only 22% of the samples were collected at the recommended ag, and most of the samples were collected between the ages of 8 and 30 days. The median age at collection was 12 days. It was observed that the service had difficulties in recalling suspected cases and financial difficulties in obtaining laboratorial reagents. CONCLUSIONS: The age at the time of collection and the delay at the diagnostic confirmation stage were the principal reasons for the delay in the initiation of treatment of the cases detected by the service.
Asunto(s)
Humanos , Recién Nacido , Hipotiroidismo Congénito/epidemiología , Tamizaje Neonatal/normas , Evaluación de Programas y Proyectos de Salud , Fenilcetonurias/epidemiología , Factores de Edad , Brasil/epidemiología , Estudios Transversales , Tamizaje Neonatal/economía , Prevalencia , Factores de TiempoRESUMEN
La fenilcetonuria es una enfermedad metabólico hereditaria, causada por deficiencia de la enzima fenilalanina β hidroxilasa o de su cofactor, la tetrahidrobiopterina, la cual conlleva al individuo afectado al retraso mental si no se realiza el diagnóstico y tratamiento oportuno. Se presenta con una frecuencia de 2-6 casos por cada 100 000 habitantes en Europa y Norteamérica, mientras que en Cuba es de 1 por cada 50 000 nacimientos. Esta entidad se puede diagnosticar mediante pruebas que detecten la presencia de fenilalanina en sangre para identificar los niños fenilcetonúricos. Actualmente, se utiliza en Cuba el Sistema Ultramicroanalítico (SUMA) con probada efectividad, que garantiza la rapidez de los resultados. El tratamiento precoz previene los daños al sistema nervioso central y evita el retraso mental en el paciente. Algunos investigadoresse dedican al desarrollo de una versión de la enzima faltante mediante la ingeniería genética y otros exploran la posibilidad de tratar la fenilcetonuria conterapia genética (AU)
Asunto(s)
Humanos , Recién Nacido , Fenilcetonurias/diagnóstico , Fenilcetonurias/epidemiología , Fenilcetonurias/terapiaRESUMEN
Introdução: A Fenilcetonúria Clássica é causada pela deficiência da enzima hepática fenilalaninahidroxilase. Se não diagnosticada e tratada precocemente, causa retardo mental. O objetivo deste estudo foi identificar indivíduos submetidos à triagem neonatal no Rio Grande do Sul entre 1986 e 2003, com teste positivo para hiperfenilalaninemia, estimar a prevalência de hiperfenilalaninemias, verificar níveis de controle e correlacionar os anos de realização do teste, início do tratamento, evolução e quadro clínico. Métodos: Casos de hiperfenilalaninemia foram identificados nos laboratórios e clínicas de tratamento. Foi aplicado questionário, contendo variáveis demográficas e sobre a patologia, o desenvolvimento infantil, a escolaridade, o aconselhamento genético e o rastreamento neonatal. Foram avaliados pacientes entre 6 meses e 16 anos de idade. Na análise estatística, utilizou-se o teste do qui-quadrado e ANOVA para avaliar a associação entre ano do diagnóstico e controle de fenilalanina e regressão logística para avaliar o efeito conjunto de idade do diagnóstico e controle de fenilalanina sobre o atraso no desenvolvimento. Resultados: De 1986 a 2003, 418 crianças apresentaram teste positivo para fenilalanina. Destes, 351 (84,0%) apresentaram resultados normais na segunda amostra, 58 (13,9%) foram considerados portadores de hiperfenilalaninemia e 9 (2,1%) tiveram o seguimento perdido. A cobertura do programa foi de 50%. Sobre o aconselhamento genético, 39 entrevistados (72,2%) responderam não saber, não lembrar ou deram respostas incorretas. Conclusão: Não se observou tendência histórica do diagnóstico ter se tornado mais precoce ou do controle laboratorial ter se tornado melhor. O controle bioquímico da fenilalanina não dependeu da precocidade do diagnóstico e sim, da idade dos pacientes.
Introduction: Classical phenylketonuria is caused by deficiency of the hepatic enzyme phenylalanine hydroxylase. If not diagnosed and treated early, it causes mental retardation. The aim of this study was to identify patients who underwent neonatal screening in Rio Grande do Sul between 1986 and 2003 and tested positive for hyperphenylalaninemia, to estimate the prevalence of hyperphenyl-alaninaemias, to check the levels of control, and to correlate the years of testing, initiation of treatment, evolution and clinical picture. Methods: Cases of hyperphenylalaninemia were identified in laboratories and treatment clinics. A questionnaire was administered containing demographic variables and about the pathology, child development, education, genetic counseling and neonatal screening. We evaluated patients between 6 months and 16 years of age. The statistical analysis used the chi-square test and ANOVA to assess the association between year of diagnosis and control of phenylalanine and logistic regression to assess the combined effect of age at diagnosis and control of phenylalanine on the developmental delay. Results: From 1986 to 2003, 418 children tested positive for phenylalanine. Of these, 351 (84.0%) had normal results in the second sample, 58 (13.9%) were considered with hyperphenylalaninemia, and 9 (2.1%) were lost for follow-up . The coverage of the program was 50%. Concerning genetic counseling, 39 respondents (72.2%) reported not knowing, not remembering or gave incorrect answers. Conclusion: There was no historical trend of diagnosis having become earlier or of laboratory control having improved. The biochemical control of phenylalanine was dependent on patient age rather than on early diagnosis.
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Preescolar , Niño , Adolescente , Fenilalanina Hidroxilasa/deficiencia , Fenilalanina Hidroxilasa/metabolismo , Mortalidad Fetal , Tamizaje Neonatal , Estudios de Cohortes , Factores de Riesgo , Fenilcetonurias/diagnóstico , Fenilcetonurias/epidemiologíaRESUMEN
Os objetivos deste trabalho foram: agrupar informações relevantes à fenilcetonúria, destacando causa, sintomas, tratamento dietético, prevalência nacional e internacional; e identificar a situação do Brasil quanto a essa disfunção metabólica. Foi realizado um levantamento de dados junto ao Ministério da Saúde e aos vários centros de tratamento para fenilcetonúricos no Brasil. Neste estudo foram localizados 1.225 casos de portadores da doença, que recebiam controle e assistência. Um dos principais problemas detectados foi que, na maioria das regiões brasileiras, portadores de fenilcetonúria precisam deslocar-se de seus estados, procurando centros mais capacitados para o tratamento. Nas regiões Norte e Nordeste são poucas as informações disponíveis. Com os resultados obtidos conclui-se que, nem a triagem neonatal, nem os centros de tratamento para fenilcetonúria cobrem todos os casos brasileiros. O Brasil está avançando na organização de dados e ações relativas à fenilcetonúria. Os alimentos específicos são restritos e de alto custo. Novas opções estão sendo pesquisadas, porém, há muito para ser feito, principalmente em pesquisa e produção de alimentos.